Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

Authors：Qiu, Bin; Cai, Kaican; Chen, Chun; Chen, Jun; Chen, Ke-Neng; Chen, Qi-Xun; Cheng, Chao; Dai, Tian-Yang; Fan, Junqiang; Fan, Zhaohui; Hu, Jian; Hu, Wei-Dong; Huang, Yun-Chao; Jiang, Ge-Ning; Jiang, Jie; Jiang, Tao; Jiao, Wen-Jie; Li, He-Cheng; Li, Qiang; Liao, Yong-De; Liu, Hong-Xu; Liu, Jun-Feng; Liu, Lunxu; Liu, Yang; Long, Hao; Luo, Qing-Quan; Ma, Hai-Tao; Mao, Nai-Quan; Pan, Xiao-Jie; Tan, Fengwei; Tan, Li-Jie; Tian, Hui; Wang, Dong; Wang, Wen-Xiang; Wei, Li; Wu, Nan; Wu, Qing-Chen

Source：Translational Lung Cancer Research, 2021, 10(9): 3713-3736.

DOI：10.21037/tlcr-21-634

• STAGING PROJECT PROPOSALS
• FORTHCOMING 8TH EDITION
• NEOADJUVANT CHEMOTHERAPY
• SINGLE-ARM
• PREOPERATIVE CHEMOTHERAPY
• HISTOPATHOLOGIC RESPONSE
• TNM CLASSIFICATION
• OPEN-LABEL
• MULTICENTER
• NSCLC

The treatment of lung cancer is one of the major challenges in the field of oncology. According to statistics from the National Cancer Center of China in 2015, lung cancer has the highest incidence and mortality, with 733,300 new cases and 610,200 deaths across the country (1). About 85% of lung cancers are non-small cell lung cancer (NSCLC), of which 30% to 40% are considered resectable tumors, including most stage I-II and a small portion of stage IIIA tumors (2). Very early-stage NSCLC (IA) can be cured by surgery. However, more than 50% of NSCLC patients who undergo surgical treatment will relapse or metastasize within 5 years. Even if there is no lymph node metastasis and the primary

• Institution
  南方医科大学; 电子科技大学; 河北医科大学; 1; 山东大学; 上海交通大学; 中山大学; 厦门大学; 哈尔滨医科大学; 四川大学; 华中科技大学; 中国科学院研究生院; 中国人民解放军第四军医大学; 复旦大学; 青岛大学; 浙江大学; 同济大学; 中国医学科学院; 南京大学; 武汉大学; 中国医学科学院北京协和医院; 苏州大学; 中国医科大学